Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators.

Kidney Int. 2019 Mar 9. pii: S0085-2538(19)30041-9. doi: 10.1016/j.kint.2018.11.044. [Epub ahead of print]

PMID:
30898339
2.

Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease.

Edwards ME, Blais JD, Czerwiec FS, Erickson BJ, Torres VE, Kline TL.

Clin Kidney J. 2019 Feb;12(1):71-77. doi: 10.1093/ckj/sfy078. Epub 2018 Aug 29.

3.

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.

Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD.

Kidney Int Rep. 2017 Jul 21;2(6):1132-1140. doi: 10.1016/j.ekir.2017.07.004. eCollection 2017 Nov.

4.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

5.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.

6.

Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.

Kline TL, Korfiatis P, Edwards ME, Blais JD, Czerwiec FS, Harris PC, King BF, Torres VE, Erickson BJ.

J Digit Imaging. 2017 Aug;30(4):442-448. doi: 10.1007/s10278-017-9978-1.

7.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079. No abstract available.

PMID:
28444221
8.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043.

9.

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.

Gralla RJ, Ahmad F, Blais JD, Chiodo J 3rd, Zhou W, Glaser LA, Czerwiec FS.

Cancer Med. 2017 Apr;6(4):723-729. doi: 10.1002/cam4.805. Epub 2017 Mar 2.

10.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

Am J Nephrol. 2017;45(3):257-266. doi: 10.1159/000456087. Epub 2017 Feb 7.

11.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.

J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5.

12.

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators.

Am J Kidney Dis. 2017 Feb;69(2):210-219. doi: 10.1053/j.ajkd.2016.08.028. Epub 2016 Nov 14.

13.

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.

Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE.

Kidney Int Rep. 2016 Aug 6;1(4):213-220. doi: 10.1016/j.ekir.2016.08.001. eCollection 2016 Nov.

14.

Prevalence of autosomal dominant polycystic kidney disease in the European Union.

Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS.

Nephrol Dial Transplant. 2017 Aug 1;32(8):1356-1363. doi: 10.1093/ndt/gfw240.

15.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators.

Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.

16.

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.

Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA.

Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3.

17.

A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity.

Blais JD, Chin KT, Zito E, Zhang Y, Heldman N, Harding HP, Fass D, Thorpe C, Ron D.

J Biol Chem. 2010 Jul 2;285(27):20993-1003. doi: 10.1074/jbc.M110.126599. Epub 2010 May 4.

18.

Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.

Blais JD, Addison CL, Edge R, Falls T, Zhao H, Wary K, Koumenis C, Harding HP, Ron D, Holcik M, Bell JC.

Mol Cell Biol. 2006 Dec;26(24):9517-32. Epub 2006 Oct 9.

19.

Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death.

Ungureanu NH, Cloutier M, Lewis SM, de Silva N, Blais JD, Bell JC, Holcik M.

J Biol Chem. 2006 Jun 2;281(22):15155-63. Epub 2006 Apr 4.

20.

Internal translation initiation mediated by the angiogenic factor Tie2.

Park EH, Lee JM, Blais JD, Bell JC, Pelletier J.

J Biol Chem. 2005 Jun 3;280(22):20945-53. Epub 2005 Mar 31.

21.
22.

Activating transcription factor 4 is translationally regulated by hypoxic stress.

Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C, Wouters BG, Bell JC.

Mol Cell Biol. 2004 Sep;24(17):7469-82.

Supplemental Content

Loading ...
Support Center